½ÃÀ庸°í¼­
»óǰÄÚµå
1630934

°í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : »ç¿ë ¹æ¹ýº°, Àç·áº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

High Pressure Balloon Catheter Market Size, Share & Trends Analysis Report By Use, By Material, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 221 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è °í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 50¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 8.90%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀåÀº ½ÉÇ÷°ü ÁßÀç¼úÀÇ ¹ßÀü, °ü»óµ¿¸Æ ÁúȯÀÇ À¯º´·ü Áõ°¡, °í·ÉÈ­ Àα¸ÀÇ Áõ°¡ µîÀ¸·Î ÀÎÇØ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. °í¾Ð dz¼± Ä«Å×ÅÍ´Â ´Ù¾çÇÑ ÀÇ·á ½Ã¼ú, ƯÈ÷ Á¼¾ÆÁö°Å³ª ¸·Èù Ç÷°üÀ» Ä¡·áÇÏ´Â Ç÷°ü¼ºÇü¼ú¿¡ »ç¿ëµÇ´Â Ư¼ö ÀåÄ¡ÀÔ´Ï´Ù. ÀÌ Ä«Å×ÅÍ´Â ÇùÂøµÈ Ç÷°üÀ» È¿°úÀûÀ¸·Î È®ÀåÇϱâ À§ÇØ ³ôÀº ¾Ð·ÂÀ¸·Î ÆØÃ¢Çϱ⠶§¹®¿¡ ÁßÀçÀû ½ÉÀåÇÐ ¹× ¹æ»ç¼±Çп¡¼­ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀåÀ» ÁÖµµÇÏ´Â ¸î °¡Áö Áß¿äÇÑ ¿äÀÎÀº Àü ¼¼°èÀûÀ¸·Î ÀÌȯÀ²°ú »ç¸Á·üÀÇ ÁÖ¿ä ¿øÀÎÀÎ ½ÉÇ÷°üÁúȯ(CVDs)ÀÇ ¹ß»ý·ü Áõ°¡¿Í °°Àº ¸î °¡Áö Áß¿äÇÑ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC)¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â ¸Å³â ¾à 80¸¸ 5,000¸íÀÌ ½ÉÀ帶ºñ¸¦ °æÇèÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áß ¾à 60¸¸ 5,000¸íÀº óÀ½À¸·Î ½ÉÀ帶ºñ¸¦ °æÇèÇÑ »ç¶÷À̰í, ¾à 20¸¸ ¸íÀº °ú°Å¿¡ ½ÉÀ帶ºñ¸¦ °æÇèÇÑ ÀûÀÌ ÀÖ´Â »ç¶÷ÀÔ´Ï´Ù. ¶ÇÇÑ Àü ¼¼°èÀûÀ¸·Î ºñ¸¸, °íÇ÷¾Ð, ´ç´¢º´ÀÇ Áõ°¡´Â ½ÉÇ÷°ü ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÀÚ±ØÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº ½ÃÀå »óȲ Çü¼º¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °¢ Á¦Á¶¾÷ü´Â ±â¼ú Çõ½Å¿¡ Á¡Á¡ ´õ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸¸ç, ¿ì¼öÇÑ Àç·á, Çâ»óµÈ ³»±¸¼º, Çâ»óµÈ ¼º´É Ư¼ºÀ» °®Ãá Â÷¼¼´ë dz¼± Ä«Å×Å͸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í ½Ã¼ú ÇÕº´ÁõÀ» °¨¼Ò½ÃÄÑ ´Ù¾çÇÑ ÀÇ·á ÇöÀå¿¡¼­ dz¼± Ä«Å×ÅÍÀÇ Ã¤ÅÃÀÌ Àü¹ÝÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«·Î ±¸ºÐµË´Ï´Ù. ºÏ¹Ì´Â ¼±ÁøÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº ÀÇ·áºñ, ½ÉÇ÷°üÁúȯÀ» ¾Î°í ÀÖ´Â Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ ½ÃÀå¿¡¼­ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡´Â ÁÖ¿ä ±â¾÷µéÀÌ Á¸ÀçÇÏ°í ²÷ÀÓ¾ø´Â ±â¼ú Çõ½ÅÀÌ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ ½ÃÀåÀÇ ¸®´õ½Ê¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

±×·¯³ª ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇコÄɾî ÅõÀÚ Áõ°¡, »ýȰ½À°üº´ À¯º´·ü Áõ°¡, ½ÉÇ÷°ü °Ç°­¿¡ ´ëÇÑ »ç¶÷µéÀÇ ÀÎ½Ä Áõ°¡°¡ ÀÌ Áö¿ªÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àεµ, Áß±¹ µî ½ÅÈï±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®ÃæÀº ½ÃÀå ÁøÀÔÀڵ鿡°Ô Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

°í¾Ð dz¼± Ä«Å×ÅÍÀÇ ±ÔÁ¦ ȯ°æÀº ±â¼ú ¹ßÀü, ÀÇ·á °üÇàÀÇ º¯È­, »õ·Î¿î °úÇÐÀû µ¥ÀÌÅÍ¿¡ µû¶ó ²÷ÀÓ¾øÀÌ ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü´Â ±ÔÁ¦¿¡ ´ëÇÑ ÃֽŠÁ¤º¸¸¦ Áö¼ÓÀûÀ¸·Î ÆÄ¾ÇÇÏ°í ±×¿¡ µû¶ó ¾÷¹«¿Í Á¦Ç°À» Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï ÁغñÇØ¾ß ÇÕ´Ï´Ù.

½ÃÀå °æÀïÀÌ Ä¡¿­ÇØÁö°í ÀÖÀ¸¸ç, »õ·Î¿î ±â¾÷µéÀÌ Á¤±âÀûÀ¸·Î ÀÌ ºÐ¾ß¿¡ ÁøÀÔÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸ ±â¾÷µéÀº Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ½Å»ý ±â¾÷ÀÇ ¾Ð¹Ú¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æÀïÀÇ °ÝÈ­´Â °¡°ÝÀ» ³·Ãß°í ÀÌÀ±À²¿¡ ¿µÇâÀ» ¹ÌÃÄ Á¦Á¶¾÷ü°¡ °æ¿µÀ» À¯ÁöÇÏ±â ¾î·Æ°Ô ¸¸µé ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ Á¦Ç°À» Â÷º°È­Çϰí È¿°úÀûÀÎ ¸¶ÄÉÆÃ Àü·«À» äÅÃÇØ¾ß ÇÕ´Ï´Ù.

°í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ¿ëµµº°·Î´Â Ç÷°ü¼ºÇü¼ú, ½ºÅÙÆ®»ðÀÔ¼ú°ú °°Àº ÁßÀçÀû Ä¡·á¿¡ ÇʼöÀûÀ̸ç, ÇùÂøµÈ µ¿¸ÆÀ» È®ÀåÇϰí Ç÷·ù¸¦ ȸº¹½ÃÄÑ È¯ÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¥ »ç¿ëµÇ±â ¶§¹®¿¡ Ä¡·á¿ë ºÐ¾ß°¡ 2024³â ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
  • ¼ÒÀ纰·Î´Â ³ªÀÏ·Ð ºÎ¹®ÀÌ 2024³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ³ôÀº ÀÎÀå °­µµ, À¯¿¬¼º ¹× ³»±¸¼ºÀ¸·Î ÀÎÇØ °í¾Ð ÀÀ¿ë ºÐ¾ß¿¡ ÀÌ»óÀûÀÎ ¼±ÅÃÀÔ´Ï´Ù.
  • ¿ëµµº°·Î´Â ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÎÅͺ¥¼Ç ±â¼úÀÇ ¹ßÀü, dz¼± Ä«Å×ÅÍ ±â¼úÀÇ È¿°ú, ÃÖ¼Òħ½ÀÀû Á¢±Ù¹ýÀ» ¼±È£ÇÏ´Â ÀÇ·á ȯ°æÀÇ ÁøÈ­·Î ÀÎÇØ ½ÉÀ庴 ºÐ¾ß°¡ 2024³â ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â ¼ö¼ú Áõ°¡, ±â¼ú ¹ßÀü, ÃÖ¼Òħ½ÀÀû °³ÀÔ¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ȯÀÚ Ä¡·á ±âÁØ °³¼±, º´¿ø ±â¹Ý Ä¡·á¸¦ Áö¿øÇÏ´Â ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©ÀÇ ¹ßÀü µîÀ¸·Î ÀÎÇØ º´¿ø ºÎ¹®ÀÌ 2024³â ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
  • Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÁÖ¿ä ½ÃÀå ±â¾÷ÀÎ Boston Scientific Corporation, Medtronic, Terumo Medical Corporation µîÀÌ Á¸ÀçÇϱ⠶§¹®À̸ç, ¹Ì±¹À» ºñ·ÔÇÑ ºÏ¹Ì ±¹°¡¿¡¼­ ÀÔÁö¸¦ È®ÀåÇϰí ÀÖ´Â ¿©·¯ ±â¾÷ÀÌ Á¸ÀçÇϱ⠶§¹®ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå °í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • °í¾Ð dz¼± Ä«Å×ÅÍ ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå °í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå : ºÎ¹® ºÐ¼®, »ç¿ë ¹æ¹ýº°, 2018-2030³â(¹é¸¸ ´Þ·¯)

  • Á¤ÀÇ¿Í ¹üÀ§
  • »ç¿ë ¹æ¹ý ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â¡¤2030³â
  • ¼¼°èÀÇ °í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå, »ç¿ë ¹æ¹ýº°, 2018-2030³â
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, 2018-2030³â

Á¦5Àå °í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå : ºÎ¹® ºÐ¼®, Àç·áº°, 2018-2030³â(¹é¸¸ ´Þ·¯)

  • Á¤ÀÇ¿Í ¹üÀ§
  • Àç·á ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â¡¤2030³â
  • ¼¼°èÀÇ °í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå, Àç·áº°, 2018-2030³â
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, 2018-2030³â

Á¦6Àå °í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå : ºÎ¹® ºÐ¼®, ¿ëµµº°, 2018-2030³â(¹é¸¸ ´Þ·¯)

  • Á¤ÀÇ¿Í ¹üÀ§
  • ¿ëµµ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â¡¤2030³â
  • ¼¼°èÀÇ °í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå, ¿ëµµº°, 2018-2030³â
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, 2018-2030³â

Á¦7Àå °í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå : ºÎ¹® ºÐ¼®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â(¹é¸¸ ´Þ·¯)

  • Á¤ÀÇ¿Í ¹üÀ§
  • ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â¡¤2030³â
  • ¼¼°èÀÇ °í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, 2018-2030³â

Á¦8Àå °í¾Ð dz¼± Ä«Å×ÅÍ ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ª ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â :
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï ±¸µµ

  • ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
  • ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®, ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷º°
  • ±â¾÷ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Boston Scientific Corporation
    • ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
    • APR Medtech Ltd
    • Medtronic
    • Terumo Medical Corporation
    • Nipro Medical Corporation
    • Cordis
    • Relisys Medical Devices Limited
    • Advin Health Care
    • Nordson Corporation
    • Biomerics
    • Shanghai VasoLutions MedTech Co. Ltd.
    • MicroPort Scientific Corporation
    • KANEKA CORPORATION
    • OrbusNeich Medical Group Holdings Limited
    • SIS Medical AG
    • Merit Medical Systems
ksm 25.02.03

High Pressure Balloon Catheter Market Growth & Trends:

The global high pressure balloon catheter market size is anticipated to reach USD 5.03 billion by 2030 and is anticipated to grow at a CAGR of 8.90% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is witnessing substantial growth, fueled by advancements in cardiovascular interventions, increased prevalence of coronary artery diseases, and a rising aging population. High-pressure balloon catheters are specialized devices used in various medical procedures, particularly in angioplasty to treat narrowed or blocked blood vessels. These catheters expand to a high pressure to ensure effective dilation of stenosed vessels, making them indispensable in interventional cardiology and radiology.

The market is driven by several key factors, including the rising incidence of cardiovascular diseases (CVDs), which have become a leading cause of morbidity and mortality worldwide. According to the U.S. Centers for Disease Control and Prevention (CDC), each year, approximately 805,000 people in the U.S. experience a heart attack. Among these cases, about 605,000 are first-time heart attack sufferers, while around 200,000 occur in people who have previously had a heart attack. In addition, the global increase in obesity, hypertension, and diabetes has catalyzed the demand for cardiovascular procedures, further propelling the growth of the market.

Technological advancements play a crucial role in shaping the market landscape. Manufacturers are increasingly focusing on innovation, developing next-generation balloon catheters with superior materials, enhanced durability, and improved performance characteristics. These advancements lead to better patient outcomes, reduced procedural complications, and an overall increase in the adoption of balloon catheters in different healthcare settings.

Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America holds a significant share of the market, driven by advanced healthcare infrastructure, high healthcare expenditure, and a growing population of individuals with cardiovascular conditions. The presence of major key players and constant innovation in this region contribute to its market leadership.

However, Asia-Pacific is expected to exhibit the fastest growth rate during the forecast period. Rising healthcare investments, the growing prevalence of lifestyle-related diseases, and an increasing awareness of cardiovascular health among the population are key drivers in this region. In addition, the expansion of healthcare infrastructure in emerging economies such as India and China creates substantial growth opportunities for market players.

The regulatory landscape for high pressure balloon catheters is continually evolving, responding to advancements in technology, changes in healthcare practices, and emerging scientific data. Manufacturers must stay informed of regulatory updates and be prepared to adapt their practices and products accordingly.

The market is becoming increasingly competitive, with new players entering the field regularly. Established companies face pressure from start-ups offering innovative solutions. This heightened competition may drive down prices, impacting profit margins and making it harder for manufacturers to sustain their operations. Companies must differentiate their products and adopt effective marketing strategies to maintain a competitive edge.

High Pressure Balloon Catheter Market Report Highlights:

  • Based on the use, the therapeutic segment dominated the market in 2024 as they are essential in interventional procedures particularly angioplasty and stent placement, where they are used to dilate narrowed arteries, thereby restoring blood flow and improving patient outcomes.
  • Based on the material, the nylon segment dominated the market in 2024 owing to its high tensile strength, flexibility, and durability, making it an ideal choice for high-pressure applications.
  • Based on the application, the cardiology segment dominated the market in 2024 owing to rising prevalence of cardiovascular diseases, advancements in interventional techniques, the efficacy of balloon catheter technologies, and an evolving healthcare landscape that prioritizes minimally invasive approaches.
  • Based on the end use, the hospitals segment dominated the market in 2024 owing to owing to increasing number of surgical procedures, advancements in technology, a growing preference for minimally invasive interventions, improved patient care standards, and the evolution of regulatory frameworks that support hospital-based care.
  • Based on region, North America region dominated the market owing to factors such as the presence of key market players Boston Scientific Corporation, Medtronic, Terumo Medical Corporation, among others and is expected to register the fastest growth over the forecast period due to several companies expanding their presence in North America countries like U.S.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Use
    • 1.2.2. Material
    • 1.2.3. Application
    • 1.2.4. End-use
    • 1.2.5. Regional Scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. High Pressure Balloon Catheter Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of cardiovascular diseases
      • 3.2.1.2. Growing demand of minimally invasive procedures
      • 3.2.1.3. Rising awareness of the benefits of advanced catheter technologies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of procedures and devices
  • 3.3. High Pressure Balloon Catheter Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. High Pressure Balloon Catheter Market: Segment Analysis, By Use, 2018 - 2030 (USD Million)

  • 4.1. Definition and Scope
  • 4.2. Use Market Share Analysis, 2024 & 2030
  • 4.3. Global High Pressure Balloon Catheter Market, by Use, 2018 to 2030
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 4.4.1. Diagnostic
      • 4.4.1.1. Diagnostic market, 2018 - 2030 (USD Million)
    • 4.4.2. Therapeutic
      • 4.4.2.1. Therapeutic market, 2018 - 2030 (USD Million)

Chapter 5. High Pressure Balloon Catheter Market: Segment Analysis, By Material, 2018 - 2030 (USD Million)

  • 5.1. Definition and Scope
  • 5.2. Materials Market Share Analysis, 2024 & 2030
  • 5.3. Global High Pressure Balloon Catheter Market, by Materials, 2018 to 2030
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 5.4.1. Nylon
      • 5.4.1.1. Nylon market, 2018 - 2030 (USD Million)
    • 5.4.2. Polyester
      • 5.4.2.1. Polyester market, 2018 - 2030 (USD Million)

Chapter 6. High Pressure Balloon Catheter Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 6.1. Definition and Scope
  • 6.2. Application Market Share Analysis, 2024 & 2030
  • 6.3. Global High Pressure Balloon Catheter Market, by Application, 2018 to 2030
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 6.4.1. Cardiology
      • 6.4.1.1. Cardiology market, 2018 - 2030 (USD Million)
    • 6.4.2. Urology
      • 6.4.2.1. Urology market, 2018 - 2030 (USD Million)
    • 6.4.3. Nephrology
      • 6.4.3.1. Nephrology market, 2018 - 2030 (USD Million)
    • 6.4.4. Others
      • 6.4.4.1. Others market, 2018 - 2030 (USD Million)

Chapter 7. High Pressure Balloon Catheter Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

  • 7.1. Definition and Scope
  • 7.2. End-use Market Share Analysis, 2024 & 2030
  • 7.3. Global High Pressure Balloon Catheter Market, by End Use, 2018 to 2030
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 7.4.1. Hospitals
      • 7.4.1.1. Hospitals market, 2018 - 2030 (USD Million)
    • 7.4.2. Ambulatory Surgical Centers (ASCs)
      • 7.4.2.1. Ambulatory Surgical Centers (ASCs) market, 2018 - 2030 (USD Million)
    • 7.4.3. Specialty Clinics
      • 7.4.3.1. Specialty clinics market, 2018 - 2030 (USD Million)
    • 7.4.4. Others
      • 7.4.4.1. Others market, 2018 - 2030 (USD Million)

Chapter 8. High Pressure Balloon Catheter Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Recent Developments & Impact Analysis by Key Market Participants
  • 9.3. Company Market Share Analysis, 2024
  • 9.4. Key Company Profiles
    • 9.4.1. Boston Scientific Corporation
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. APR Medtech Ltd
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Medtronic
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Terumo Medical Corporation
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Nipro Medical Corporation
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Cordis
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Relisys Medical Devices Limited
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Advin Health Care
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Nordson Corporation
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. Biomerics
      • 9.4.11.1. Company overview
      • 9.4.11.2. Financial performance
      • 9.4.11.3. Product benchmarking
      • 9.4.11.4. Strategic initiatives
    • 9.4.12. Shanghai VasoLutions MedTech Co. Ltd.
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Product benchmarking
      • 9.4.12.4. Strategic initiatives
    • 9.4.13. MicroPort Scientific Corporation
      • 9.4.13.1. Company overview
      • 9.4.13.2. Financial performance
      • 9.4.13.3. Product benchmarking
      • 9.4.13.4. Strategic initiatives
    • 9.4.14. KANEKA CORPORATION
      • 9.4.14.1. Company overview
      • 9.4.14.2. Financial performance
      • 9.4.14.3. Product benchmarking
      • 9.4.14.4. Strategic initiatives
    • 9.4.15. OrbusNeich Medical Group Holdings Limited
      • 9.4.15.1. Company overview
      • 9.4.15.2. Financial performance
      • 9.4.15.3. Product benchmarking
      • 9.4.15.4. Strategic initiatives
    • 9.4.16. SIS Medical AG
      • 9.4.16.1. Company overview
      • 9.4.16.2. Financial performance
      • 9.4.16.3. Product benchmarking
      • 9.4.16.4. Strategic initiatives
    • 9.4.17. Merit Medical Systems
      • 9.4.17.1. Company overview
      • 9.4.17.2. Financial performance
      • 9.4.17.3. Product benchmarking
      • 9.4.17.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦